Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Neurology

• Publication date

  2016-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1212/WNL.0000000000002418PMID 26843559PMCID PMC4793783
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Biomarkers of 'acute-onset' chronic inflammatory demyelinating polyneuropathy.

  2015cited by this paper
• Destruction of paranodal architecture in inflammatory neuropathy with anti-contactin-1 autoantibodies

  2015cited by this paper
• A nationwide survey of combined central and peripheral demyelination in Japan

  2015cited by this paper
• Contactin 1 IgG4 associates to chronic inflammatory demyelinating polyneuropathy with sensory ataxia.

  2015cited by this paper
• Guillain–Barré and Miller Fisher syndromes—new diagnostic classification

  2014cited by this paper
• Different IVIG Glycoforms Affect In Vitro Inhibition of Anti-Ganglioside Antibody-Mediated Complement Deposition

  2014cited by this paper
• Guillain–Barré and Miller Fisher syndromes—new diagnostic classification

  2014cited by this paper
• Diagnosis and treatment of chronic acquired demyelinating polyneuropathies

  2014cited by this paper
• Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg

  2014cited by this paper
• Specific Contactin N-Glycans Are Implicated in Neurofascin Binding and Autoimmune Targeting in Peripheral Neuropathies*

  2014cited by this paper
• Efficacy and safety of Privigen® in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study)

  2013cited by this paper
• Long‐term outcome in chronic inflammatory demyelinating polyneuropathy patients treated with intravenous immunoglobulin: A retrospective study

  2013cited by this paper
• Anti-neurofascin antibody in patients with combined central and peripheral demyelination

  2013cited by this paper
• Autoimmune disorders affecting both the central and peripheral nervous system.

  2012cited by this paper
• Neurofascin as a target for autoantibodies in peripheral neuropathies

  2012influential reference
• Antibodies to gliomedin cause peripheral demyelinating neuropathy and the dismantling of the nodes of Ranvier.

  2012cited by this paper
• In Vivo Deletion of Immunoglobulin Domains 5 and 6 in Neurofascin (Nfasc) Reveals Domain-Specific Requirements in Myelinated Axons

  2010cited by this paper
• The C‐terminal domain of βIV‐spectrin is crucial for KCNQ2 aggregation and excitability at nodes of Ranvier

  2010cited by this paper
• European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society – First Revision

  2010cited by this paper
• European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society — First Revision

  2010cited by this paper
• Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial.

  2008cited by this paper
• Cell adhesion and neurite outgrowth are promoted by neurofascin NF155 and inhibited by NF186.

  2005cited by this paper
• IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides.

  2005cited by this paper
• Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies.

  2004cited by this paper
• Neurofascin is a glial receptor for the paranodin/Caspr-contactin axonal complex at the axoglial junction.

  2002cited by this paper
• Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

  2001cited by this paper
• Axon-glia interactions and the domain organization of myelinated axons requires neurexin IV/Caspr/Paranodin.

  2001cited by this paper
• Contactin orchestrates assembly of the septate-like junctions at the paranode in myelinated peripheral nerve.

  2001cited by this paper

• Immunotherapies in chronic immune-mediated neuropathies.

  2026cites this paper
• B Cell Tolerance and BCR Signaling Dysregulation in NF155-Mediated Autoimmune Nodopathies

  2025cites this paper
• Neurofascin 155, 186 and 140 Antibodies in Patients with Multiple Sclerosis: A Pilot Prospective Exploratory Study.

  2025cites this paper
• The immunology and neuropathology of the autoimmune nodopathies.

  2025cites this paper
• Epitope Mapping of Anti‐Neurofascin 155 Antibody in a Large Cohort of Autoimmune Nodopathy Patients

  2025cites this paper
• The Elusive B Cell Antigen in Multiple Sclerosis: Time to Rethink CNS B Cell Functions

  2025cites this paper
• Anti-contactin-1 autoimmune nodopathy with thymoma: case report and literature review

  2025cites this paper
• Autoimmune neuropathies: New guidelines and expert insights into clinical decision making.

  2025cites this paper
• Characterization of the neuromuscular manifestations in patients with IgG4-related disease: a systematic review

  2025cites this paper
• Clinical Spectrum, Pathology, and Mechanisms of Anti-LGI4 Antibody–Positive Autoimmune Nodopathy

  2025cites this paper
• Proprioceptive endings at muscle spindles as a possible target of autoantibodies.

  2025cites this paper
• Clinical characteristics of anti‐neurofascin 155 antibody‐positive autoimmune nodopathy in children

  2025cites this paper
• Genetic susceptibility of human leukocyte antigen alleles in chronic inflammatory demyelinating polyneuropathy in Korean patients

  2025cites this paper
• OTHER AUTOIMMUNE DISEASES AND MULTIPLE SCLEROSIS.

  2025cites this paper
• The activation of classical and/or lectin complement pathway for the pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy.

  2025cites this paper
• New insights into neurofilament and cytokine biomarkers: A narrative review

  2025cites this paper
• Autoimmune nodopathies: emerging insights and clinical implications.

  2025cites this paper
• Clinical, Electrophysiologic, and Pathologic Features of Anti-Contactin–Associated Protein 1 Autoimmune Nodopathy

  2025cites this paper
• Concurrent neuromyelitis optica spectrum disorder and neurofascin-155 antibody associated peripheral demyelination in a child

  2025cites this paper
• The potential role of IgG subclass in NF155-associated nodopathy for targeting therapy: a pediatric case report highlighting the efficacy of pulsed oral corticosteroids

  2025cites this paper
• The changing landscape of primary autoimmune neuropathies

  2025cites this paper
• Clinical Manifestations and Treatment Responses in Pediatric Neurofascin 155-IgG4 Autoimmune Nodopathy

  2025cites this paper
• Proteinuria is a key to suspect autoimmune nodopathies

  2024influential citation
• Immune-Mediated Neuropathies: Top 10 Clinical Pearls

  2024cites this paper
• Human-derived monoclonal autoantibodies as interrogators of cellular proteotypes in the brain.

  2024cites this paper
• IgG subclass shifts occurring at acute exacerbations in autoimmune nodopathies

  2024cites this paper
• Autoimmune Neuromuscular Disorders Associated With Neural Antibodies

  2024cites this paper
• Antibodies in immune-mediated peripheral neuropathies. Where are we in 2024?

  2024cites this paper
• Tremor Following Guillain Barré Syndrome

  2024cites this paper
• The Discovery of Autoimmune Nodopathies and the Impact of IgG4 Antibodies in Autoimmune Neurology

  2024cites this paper
• Autoimmune Nodopathy: When to Suspect and How to Treat?

  2024cites this paper
• The difference in nerve ultrasound and motor nerve conduction studies between autoimmune nodopathy and chronic inflammatory demyelinating polyneuropathy

  2024cites this paper
• Immune-mediated insights into clinical and specific autoantibodies in acute and chronic immune-mediated nodo-paranodopathies

  2024influential citation
• Membrane Proteome-Wide Screening of Autoantibodies in CIDP Using Human Cell Microarray Technology

  2024cites this paper
• Autoimmune nodopathy

  2024cites this paper
• Anti-pan-neurofascin nodopathy: cause of fulminant neuropathy

  2024cites this paper
• Combined Central and Peripheral Demyelination (CCPD) Associated with MOG Antibodies: Report of Four New Cases and Narrative Review of the Literature

  2024cites this paper
• Clinical Features of Autoimmune Nodopathy With Anti-Neurofascin-155 Antibodies in South Koreans

  2024influential citation
• An immuno-DOT diagnostic assay for autoimmune nodopathy

  2024cites this paper
• Long-term follow-up of relapse and remission of CIDP in a Chinese cohort

  2024cites this paper
• Autoantibodies Against Dihydrolipoamide S-Acetyltransferase in Immune-Mediated Neuropathies

  2024cites this paper
• Anti-neurofascin-155 antibody mediated a distinct phenotype of chronic inflammatory demyelinating polyradiculoneuropathy

  2024cites this paper
• Long‐Term Follow Up in Anti‐Contactin‐1 Autoimmune Nodopathy

  2024cites this paper
• Is systemic lupus erythematosus linked to Immunoglobulin G4 Autoantibodies?

  2024cites this paper
• Progress in the Diagnosis and Treatment of Autoimmune Nodopathies

  2024cites this paper
• The role of IgG4 in systemic lupus erythematosus: Implications for pathogenesis and therapy

  2024cites this paper
• Antibody-Mediated Nodo- and Paranodopathies

  2024cites this paper
• Les nodopathies auto-immunes : focus sur les auto-anticorps pathogènes et conduite à tenir en laboratoire

  2023cites this paper
• Autoimmune nodo‐paranodopathies 10 years later: Clinical features, pathophysiology and treatment

  2023cites this paper
• Pathology explains various mechanisms of auto‐immune inflammatory peripheral neuropathies

  2023cites this paper
• [A patient with anti-myelin oligodendrocyte glycoprotein antibody-associated combined central and peripheral demyelination with anti-galactocerebroside and anti-GM1 antibodies].

  2023cites this paper
• Molecular, Electrophysiological, and Ultrasonographic Differences in Selected Immune-Mediated Neuropathies with Therapeutic Implications

  2023cites this paper
• Clinical profile of autoimmune nodopathy with anti‐neurofascin 186 antibody

  2023cites this paper
• Acute/chronic inflammatory polyradiculoneuropathy.

  2023cites this paper
• The unique properties of IgG4 and its roles in health and disease

  2023cites this paper
• The autoimmune vulnerability of the node of Ranvier

  2023cites this paper
• Case report: Anti-CNTN1 antibody-associated nodopathies disease with asymmetric onset

  2023cites this paper
• Nodes of Ranvier in health and disease

  2023cites this paper
• Paraneoplastic Syndrome Presenting Combined Central and Peripheral Demyelination Associated with Anti-CV2/CRMP5 and Anti-NF186 Antibodies: A Case Report

  2023cites this paper
• [Diagnostic value of F wave changes in patients with Charcot-Marie-Tooth1A and chronic inflammatory demyelinating polyneuropathy].

  2023cites this paper
• Anti-LGI4 Antibody Is a Novel Juxtaparanodal Autoantibody for Chronic Inflammatory Demyelinating Polyneuropathy

  2023influential citation
• Experimental encephalomyelitis at age 90, still relevant and elucidating how viruses trigger disease

  2023cites this paper
• Clinical and pathophysiological implications of autoantibodies in autoimmune neuropathies.

  2023cites this paper
• [The significance of autoantibodies against nodal and paranodal proteins in autoimmune nodopathies].

  2023cites this paper
• Current Biomarker Strategies in Autoimmune Neuromuscular Diseases

  2023cites this paper
• Nodal–paranodal antibodies in HIV‐immune mediated radiculo‐neuropathies: Clinical phenotypes and relevance

  2023cites this paper
• Growing Spectrum of Autoimmune Nodopathies

  2023cites this paper
• Contactin-associated protein 2 autoantibodies can be associated with multifocal motor-like neuropathy: a case report

  2023cites this paper
• Clinical relevance of distinguishing autoimmune nodopathies from CIDP: longitudinal assessment in a large cohort

  2023cites this paper
• An Atypical Pediatric Presentation of a Chronic Polyradiculoneuropathy

  2023cites this paper
• CIDP: Current Treatments and Identification of Targets for Future Specific Therapeutic Intervention

  2022cites this paper
• The Role of IgG4 in Autoimmunity and Rheumatic Diseases

  2022cites this paper
• Neuropatie sensitive

  2022cites this paper
• Frequency and clinical correlates of anti-nerve antibodies in a large population of CIDP patients included in the Italian database

  2022cites this paper
• Treatment and Management of Autoimmune Neuropathies

  2022cites this paper
• Autoantibody profile in a Malaysian cohort of chronic inflammatory demyelinating polyneuropathy.

  2022cites this paper
• Polineuropatie infiammatorie demielinizzanti croniche

  2022cites this paper
• Value of Antibody Determinations in Chronic Dysimmune Neuropathies

  2022cites this paper
• Anti-pan-neurofascin antibodies induce subclass-related complement activation and nodo-paranodal damage

  2022cites this paper
• Emerging Role of Neuron-Glia in Neurological Disorders: At a Glance

  2022cites this paper
• Anti-Neurofascin Antibodies Associated with White Matter Diseases of the Central Nervous System: A Red Flag or a Red Herring?

  2022influential citation
• Case report: Autoimmune nodopathy with concurrent serum and CSF IgG4 anti-neurofascin 155 antibodies

  2022cites this paper
• French recommendations for the management of adult & pediatric chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).

  2022cites this paper
• Nodo-paranodopathies: Concepts, Clinical Implications, and Management

  2022influential citation
• IgG4 Valency Modulates the Pathogenicity of Anti–Neurofascin-155 IgG4 in Autoimmune Nodopathy

  2022cites this paper
• Autoantibodies in central nervous system and neuromuscular autoimmune disorders: A narrative review

  2022cites this paper
• Demyelinating Neuropathy with Markedly Elevated Serum IgG4 Levels and Anti-Contactin 1 IgG4 Antibody

  2022cites this paper
• Movement disorders and neuropathies: overlaps and mimics in clinical practice

  2022cites this paper
• Rituximab in chronic immune mediated neuropathies: a systematic review.

  2022cites this paper
• Tacrolimus Combined with Corticosteroids Improved the Outcome of CIDP Patients with Autoantibodies Against Paranodal Proteins

  2022cites this paper
• NDT_A_361461 1207..1217

  2022cites this paper
• Pathogenic autoantibodies in multiple sclerosis — from a simple idea to a complex concept

  2022cites this paper
• Diabetes Mellitus Is a Possible Risk Factor for Nodo-paranodopathy With Antiparanodal Autoantibodies

  2022cites this paper
• Clinical and diagnostic features of anti‐neurofascin‐155 antibody‐positive neuropathy in Han Chinese

  2022cites this paper
• Autoimmune nodopathies, an emerging diagnostic category

  2022cites this paper
• Polyneuropathies inflammatoires démyélinisantes chroniques

  2021cites this paper
• Pathophysiology of the Different Clinical Phenotypes of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

  2021cites this paper
• Clinical and Laboratory Features in Anti-NF155 Autoimmune Nodopathy

  2021cites this paper
• Update on Nodopathies of the Peripheral Nerve

  2021cites this paper
• European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision

  2021cites this paper